Skip to main content

Table 3 Risks of active tuberculosis infection during anti-TNF therapy, derived from a Cox proportional hazards model

From: Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea

  TB + group
(n = 21)
TB- group
(n = 1413)
Hazard ratio
(95% CI)
p value
Age at anti-TNF (years) 39.57 31.22 1.041 (1.014–1.069) 0.002
Age of IBD diagnosis (years) 32.81 25.70 1.039 (1.012–1.067) 0.005
Female 9 (42.9) 485 (34.3) 1.286 (0.541–3.055) 0.570
IBD type    0.660 (0.254–1.714) 0.393
 UC 6 (28.6) 323 (23.1)   
 CD 15 (71.4) 1087 (76.9)   
History of smoking 10 (47.6) 433 (30.6) 2.094 (0.889–4.932) 0.091
Previous TB history 1 (4.7) 48 (3.4) 1.297 (0.174–9.665) 0.800
Screening for LTBI    1.170 (0.417–3.284) 0.765
 IGRA + TST 15 (71.4) 951 (67.3)   
 IGRA 5 (23.8) 361 (25.5)   
LTBI 3 (14.3) 195 (13.8) 0.896 (0.262–3.066) 0.862
  1. TNF, tumor necrosis factor; IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; LTBI, latent tuberculosis infection; TB, tuberculosis